ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC

http://cancerGRACE.org/... Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC. GRACEcast 161 Lung Author: cancergrace Added: 08/14/2013
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts